Scope, claim coverage, and U.S. patent landscape for United States Patent 11,400,019 (bupivacaine free base + sucrose acetate isobutyrate + benzyl alcohol, with low 2,6-dimethylaniline and low benzyl acetate)
Executive summary: U.S. Patent 11,400,019 is a claims-and-compositions estate anchored on a specific parenteral bupivacaine free-base formulation with tightly defined impurity and excipient limits, plus container/closure and light-protective dosage-system claims. The practical enforceable scope is driven by three claim “gatekeepers”: (i) the quantitative excipient matrix (bupivacaine free base 10–15 wt%, sucrose acetate isobutyrate 63–67 wt%, benzyl alcohol 20–25 wt%), (ii) impurity/leachate control (benzyl acetate <30 mg/mL; 2,6-dimethylaniline <12 ppm, with narrower embodiments ≤10 ppm or 0.3–10 ppm), and (iii) product form and performance constraints (parenteral use in humans; sterile; 36-month stability limits in a sealed upright clear glass vial at 25°C/60% RH). Related claims expand to inclusion of bupivacaine N-oxide (≤1 wt%) and optional benzyl isobutyrate, and then attempt to extend coverage through dosage system architecture (inert closure/container materials, fluorinated polymer closure element, iron-free glass, nested light-attenuating container).
What is US Patent 11,400,019 and what does it claim?
Featured snippet answer: The patent claims a specific parenteral bupivacaine free-base composition with defined wt% excipients, controlled levels of 2,6-dimethylaniline and benzyl acetate, optional bupivacaine N-oxide and benzyl isobutyrate, and a dosage system using specified inert materials and light protection.
Claim 1 “composition core” (independent)
Claim 1 is the foundational composition claim and is where most infringement exposure concentrates.
Non-negotiable elements in Claim 1:
- Drug substance form: bupivacaine free base
- Excipient matrix (by wt% of total composition):
- bupivacaine free base: 10–15 wt%
- sucrose acetate isobutyrate (SAIB): 63–67 wt%
- benzyl alcohol: 20–25 wt%
- Other components:
- benzyl acetate present at level <30 mg/mL
- 2,6-dimethylaniline present at level <12 ppm
- Use and suitability:
- suitable for parenteral use in humans
Why this matters for scope: Any generic, authorized generic, or reformulation that changes any of the three wt% ranges (bupivacaine/SAIB/benzyl alcohol) or pushes 2,6-dimethylaniline to ≥12 ppm or benzyl acetate to ≥30 mg/mL avoids Claim 1.
Dependent claims that tighten impurity ranges
- Claim 2: 2,6-dimethylaniline ≤10 ppm
- Claim 3: 2,6-dimethylaniline 0.3–10 ppm
Scope consequence: These narrower embodiments sit inside Claim 1’s broader limit (<12 ppm). If a competitor lands between 10 and 12 ppm, it can still avoid Claims 2 and 3 while still potentially falling under Claim 1 (because Claim 1 only requires <12 ppm). A competitor targeting ≤10 ppm triggers the narrower dependent claims.
Dependent claims that add oxidation product
- Claim 4: composition further comprises bupivacaine N-oxide
- Claim 5: N-oxide <1 wt%
- Claim 6: N-oxide 0.01–1 wt%
Scope consequence: Inclusion of bupivacaine N-oxide is a branching feature. If a product intentionally suppresses N-oxide to zero (or below detection), Claims 4–6 may not apply even if Claim 1 does.
Dependent claims that define benzyl acetate range
- Claim 7: benzyl acetate 0.1 mg/mL to 20 mg/mL
Scope consequence: Claim 7 is narrower than Claim 1’s “<30 mg/mL.” A product at 21–29 mg/mL may avoid Claim 7 while potentially meeting Claim 1.
Dependent claims for additional excipient
- Claim 8: further comprises benzyl isobutyrate
- Claim 9: benzyl isobutyrate 0.1 mg/mL to 40 mg/mL
Scope consequence: Benzyl isobutyrate is optional. Products excluding it can avoid Claims 8 and 9.
Dependent claims for stability/performance in a specific container scenario
- Claim 10: 36-month stability in sealed, upright, clear glass vial at 25°C/60% RH such that 2,6-dimethylaniline remains <12 ppm
- Claim 11: same storage condition, N-oxide remains <1 wt%
- Claim 12: same storage condition, benzyl acetate remains <30 mg/mL
- Claim 13: same storage condition for benzyl isobutyrate, remains <50 mg/mL
Scope consequence: These are product-by-process/performance constraints anchored to a specific storage simulation and vial configuration. For infringement strategy, the key is whether an accused product meets the same formulation and then meets the same stability behavior. For non-infringement, challengers can attempt to show that the formulation fails the storage-limit performance.
What dosage systems are covered by US 11,400,019?
Featured snippet answer: The patent also claims container and closure systems that contain the claimed composition, including specific inert materials (iron-free glass; inert fluorinated polymer components) and a nested light-reducing container arrangement.
Claims 14–16: container and closure materials
- Claim 14: dosage system including:
- a container with inert material,
- a closure with inert material,
- the Claim 1 composition inside.
- Claim 15: closure inert material includes a fluorinated polymer
- Claim 16: container inert material includes glass that does not contain iron
Scope consequence: If a product uses the claimed formulation inside a delivery device with materially different closure/container materials, the dosage-system dependent claims can be avoided even if the composition itself remains covered.
Claims 17–18: nested light reduction
- Claim 17: dosage system:
- first container
- second container inside the first container
- second container has inert material
- first container reduces ambient visible light onto the second container
- Claim 1 composition is inside the second container
- Claim 18: the first container comprises a box
Scope consequence: This design attempts to capture packaging strategies used to manage light-driven degradation. If a competitor’s packaging does not include a light-attenuating outer container (or does so via a different mechanism/material arrangement that arguably falls outside the claim language), dosage-system coverage may be reduced.
What are the claims covering sterile formulations and overlap with Claim 1?
Featured snippet answer: Claims 19–27 recast the same formulation into a “sterile” version and preserve the same impurity and stability logic plus optional excipients and N-oxide.
Independent composition claim 19 (sterile limitation)
- Same quantitative matrix:
- bupivacaine free base 10–15 wt%
- SAIB 63–67 wt%
- benzyl alcohol 20–25 wt%
- benzyl acetate <30 mg/mL
- 2,6-dimethylaniline <12 ppm
- plus sterile
Then the dependent pattern repeats:
- Claims 20–21: narrower 2,6-dimethylaniline (≤10 ppm; 0.3–10 ppm)
- Claims 22–23: optional bupivacaine N-oxide
- Claims 22-23: (and below) optional benzyl isobutyrate
- Claims 24–27: same 36-month stability in sealed upright clear glass at 25°C/60% RH for impurity/oxidation/excipient thresholds
Overlap consequence: If an accused product is sterile and otherwise matches the formulation, both the sterile lineage (Claims 19+) and the non-sterile lineage (Claims 1+) could be implicated depending on how “sterile” is interpreted relative to the product and testing.
How do the chemical constraints map to competitive reformulation strategies?
Featured snippet answer: Competitors can target infringement avoidance by moving outside the defined wt% excipient matrix, altering the impurity endpoints (2,6-dimethylaniline and benzyl acetate), omitting optional features (N-oxide, benzyl isobutyrate), and changing packaging materials/architecture.
A. Excipient matrix “hard boundaries”
- bupivacaine free base: 10–15 wt%
- SAIB: 63–67 wt%
- benzyl alcohol: 20–25 wt%
Reformulation risk: Small shifts can eliminate coverage. If you maintain the same excipient identity but change concentration outside the band, Claim 1 and Claim 19 fail on element mismatch.
B. Impurity/spec control “hard boundaries”
- benzyl acetate: <30 mg/mL (and optionally 0.1–20 mg/mL)
- 2,6-dimethylaniline: <12 ppm (and optionally ≤10 ppm or 0.3–10 ppm)
Reformulation risk: Even if excipient bands match, impurity management is a central infringement lever. Reaching ≥12 ppm for 2,6-dimethylaniline or ≥30 mg/mL benzyl acetate avoids core claim elements, but doing so may be untenable from a regulatory and quality standpoint.
C. Optional feature “branching”
- bupivacaine N-oxide:
- claimed in Claims 4–6 and their sterile counterparts
- benzyl isobutyrate:
- claimed in Claims 8–9 and sterile counterparts
Reformulation risk: Excluding these optional ingredients avoids their dependent claims, but does not necessarily avoid the independent formulation claim if those ingredients are absent yet the rest of Claim 1 is met.
D. Performance/stability “evading via behavior”
The claims specify 36-month stability in a sealed upright clear glass vial at 25°C/60% RH.
Reformulation risk: If a product matches the composition numbers but shows higher impurity formation under the specified storage condition, it can avoid the storage-stability dependent claims (10–13, 11–13, 24–27), while still potentially falling under Claim 1/19 depending on whether those storage-dependent limitations are required.
Patent landscape: what other patents are likely relevant around this claim theme?
Featured snippet answer: This patent is scoped tightly around a specific SAIB-based bupivacaine free-base parenteral composition and impurity control for 2,6-dimethylaniline and benzyl acetate, with packaging-related claims. The surrounding landscape typically includes patents on (i) anesthetic free-base formulations, (ii) SAIB-based delivery compositions, (iii) impurity identification/limits, (iv) oxidation products and their control, and (v) container/closure material and light protection.
However, a complete landscape requires patent-number-level evidence (family members, continuations, continuations-in-part, priority links, claim chart overlap, and prosecution history). No such additional patent identifiers or bibliographic records for 11,400,019 were provided in the prompt, so an exhaustive US landscape map cannot be produced from the available inputs.
Which legal and regulatory hooks matter for enforcement and Paragraph IV-style entry planning?
Featured snippet answer: Enforcement exposure is strongest for paragraph-IV and section 505(b)(2) style entry scenarios where an ANDA or 505(b)(2) submission relies on a formulation that is composition-identical (wt% bands and impurity limits) and uses the same packaging architecture. Regulatory risk arises from the need to demonstrate sterility and maintain impurity formation profiles over 36 months in the specified vial conditions.
Practical litigation focus points (claim-construction and evidence)
- Element-by-element composition match: wt% bands and impurity thresholds.
- Impurity measurement methodology: ppm reporting, analytical methods, and sampling timepoints.
- Container definition: inert material categories (fluorinated polymer; iron-free glass) and nested light-reduction architecture.
- Stability test replication: whether accused product meets the same storage condition language.
How strong is the patent estate for 11,400,019 based on claim structure?
Featured snippet answer: The estate is strong on claim clarity for composition and impurity thresholds because the independent claims are numerically bounded. The estate is weaker on breadth to the extent competitors can redesign the excipient matrix, exceed impurity thresholds (medically and regulatorily risky), or change packaging architecture materially.
Strength drivers
- Independent claims are quantitative on core excipients and impurity/leachate limits.
- Dependent claims tighten impurity and add stability/performance constraints.
- Packaging claims add incremental protection against common device design choices.
Weakness drivers
- Tight numerical bands allow straightforward “design-around” by formulation adjustment.
- Packaging claims are specific to inert material selection and visible-light attenuation via an outer container concept.
Key takeaways
- US 11,400,019 centers on a defined SAIB/benzyl alcohol/bupivacaine free-base parenteral formulation with strict impurity limits for 2,6-dimethylaniline (<12 ppm) and benzyl acetate (<30 mg/mL).
- The independent scope is split into two composition lines: general suitability for parenteral use (Claim 1) and sterile formulations (Claim 19).
- Dependent claims lock in narrower impurity windows (≤10 ppm; 0.3–10 ppm), optional inclusion of bupivacaine N-oxide (≤1 wt%), optional benzyl isobutyrate, and 36-month stability performance in sealed upright clear glass vials at 25°C/60% RH.
- Dosage system coverage adds protection through specific container/closure material concepts (fluorinated polymer closure; iron-free glass) and a nested light-protective packaging concept (outer box reduces ambient visible light).
- Commercial risk for competitors is highest where they target near-identical formulation numbers and keep impurity profiles within the claimed endpoints, plus they match packaging architecture.
FAQs
- What concentration ranges for bupivacaine, SAIB, and benzyl alcohol trigger independent claim coverage in US 11,400,019?
- If a generic keeps 2,6-dimethylaniline at 11 ppm but benzyl acetate rises to 31 mg/mL, which claims are avoided?
- Does the patent require benzyl isobutyrate or bupivacaine N-oxide for infringement of the independent claims?
- How do the storage stability dependent claims (36 months at 25°C/60% RH in clear glass vial) affect infringement proof?
- What packaging features are needed to potentially infringe the dosage-system dependent claims (fluorinated polymer closure, iron-free glass, light-reducing outer box)?
References
- United States Patent No. 11,400,019.
